INKT Mink Therapeutics Inc

USD 9.50 0.00 ( 0.00%)
Icon

Mink Therapeutics Inc (INKT) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 9.50

0.00 (0.00%)

USD 0.04B

4.40K

USD 4.00(-57.88%)

USD 10.00 (+5.29%)

Icon

INKT

Mink Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 9.50
0.00 ( 0.00%)
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.04B

USD 10.00 (+5.29%)

USD 9.50

Mink Therapeutics Inc (INKT) Stock Forecast

Show ratings and price targets of :
USD 4.00
(-57.88%)

Based on the Mink Therapeutics Inc stock forecast from 1 analysts, the average analyst target price for Mink Therapeutics Inc is USD 4.00 over the next 12 months. Mink Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Mink Therapeutics Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Mink Therapeutics Inc’s stock price was USD 9.50. Mink Therapeutics Inc’s stock price has changed by -15.12% over the past week, +991.80% over the past month and +2.12% over the last year.

No recent analyst target price found for Mink Therapeutics Inc
No recent average analyst rating found for Mink Therapeutics Inc

Company Overview Mink Therapeutics Inc

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candida...Read More

149 Fifth Avenue, New York, NY, United States, 10010

31

December

USD

USA

Adjusted Closing Price for Mink Therapeutics Inc (INKT)

Loading...

Unadjusted Closing Price for Mink Therapeutics Inc (INKT)

Loading...

Share Trading Volume for Mink Therapeutics Inc Shares

Loading...

Compare Performance of Mink Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for INKT

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Mink Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD118.90B 32.57 220.35

Frequently Asked Questions About Mink Therapeutics Inc (INKT) Stock

Based on ratings from 1 analysts Mink Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on INKT's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for INKT is USD 4.00 over the next 12 months. The maximum analyst target price is USD 4 while the minimum anlayst target price is USD 4.

Unfortunately we do not have enough data on INKT's stock to indicate if its overvalued.

The last closing price of INKT's stock was USD 9.50.

The most recent market capitalization for INKT is USD 0.04B.

Based on targets from 1 analysts, the average taret price for INKT is projected at USD 4.00 over the next 12 months. This means that INKT's stock price may go down by -57.88% over the next 12 months.

We can't find any ETFs which contains Mink Therapeutics Inc's stock.

As per our most recent records Mink Therapeutics Inc has 31 Employees.

Mink Therapeutics Inc's registered address is 149 Fifth Avenue, New York, NY, United States, 10010. You can get more information about it from Mink Therapeutics Inc's website at https://minktherapeutics.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Frequently Asked Questions About Mink Therapeutics Inc (INKT) Stock

Based on ratings from 1 analysts Mink Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on INKT's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for INKT is USD 4.00 over the next 12 months. The maximum analyst target price is USD 4 while the minimum anlayst target price is USD 4.

Unfortunately we do not have enough data on INKT's stock to indicate if its overvalued.

The last closing price of INKT's stock was USD 9.50.

The most recent market capitalization for INKT is USD 0.04B.

Based on targets from 1 analysts, the average taret price for INKT is projected at USD 4.00 over the next 12 months. This means that INKT's stock price may go down by -57.88% over the next 12 months.

We can't find any ETFs which contains Mink Therapeutics Inc's stock.

As per our most recent records Mink Therapeutics Inc has 31 Employees.

Mink Therapeutics Inc's registered address is 149 Fifth Avenue, New York, NY, United States, 10010. You can get more information about it from Mink Therapeutics Inc's website at https://minktherapeutics.com.
Loading...